ウイルスベクターワクチン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ウイルスベクターワクチン" in Japanese language version.

refsWebsite

Global rank Japanese rank

13wikipedia.org

low place

12nih.gov

4^th place

24^th place

7doi.org

2^nd place

6^th place

6clinicaltrials.gov

5,225^th place

low place

4fda.gov

447^th place

1,043^rd place

3europa.eu

68^th place

425^th place

2web.archive.org

1^st place

1cdc.gov

218^th place

712^th place

1worldcat.org

5^th place

19^th place

1jnj.com

low place

1clinicaltrialsregister.eu

low place

1nytimes.com

7^th place

63^rd place

cdc.gov

“Understanding and Explaining Viral Vector COVID-19 Vaccines”. U.S. Centers for Disease Control and Prevention (2021年2月25日). 2021年4月2日閲覧。

clinicaltrials.gov

臨床試験番号 NCT02313077 研究名 "A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants" - ClinicalTrials.gov
臨床試験番号 NCT04400838 研究名 "Investigating a Vaccine Against COVID-19" - ClinicalTrials.gov
臨床試験番号 NCT04436471 研究名 "An Open Study of the Safety, Tolerability and Immunogenicity of the Drug 'Gam-COVID-Vac' Vaccine Against COVID-19" - ClinicalTrials.gov
臨床試験番号 NCT04436276 研究名 "A Study of Ad26.COV2.S in Adults" - ClinicalTrials.gov
臨床試験番号 NCT04505722 研究名 "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants" - ClinicalTrials.gov
臨床試験番号 NCT04566770 研究名 "Phase IIb Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)" - ClinicalTrials.gov

clinicaltrialsregister.eu

“A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19”. EU Clinical Trials Register. European Union (2020年4月21日). 2020年10月5日時点のオリジナルよりアーカイブ。2020年8月3日閲覧。

doi.org

Stephen, Sam Laurel; Montini, Eugenio; Sivanandam, Vijayshankar Ganesh; Al-Dhalimy, Muhseen; Kestler, Hans A.; Finegold, Milton; Grompe, Markus; Kochanek, Stefan (2010-10). “Chromosomal Integration of Adenoviral Vector DNA In Vivo”. Journal of Virology 84 (19): 9987–9994. doi:10.1128/JVI.00751-10. ISSN 0022-538X. PMC 2937808. PMID 20686029.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W (August 2020). “Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial”. Lancet 396 (10249): 479–488. doi:10.1016/S0140-6736(20)31605-6. PMC 7836858. PMID 32702299.
Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H (November 2011). “Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy”. The Journal of Infectious Diseases 204 Suppl 3 (suppl 3): S1066-74. doi:10.1093/infdis/jir348. PMC 3203393. PMID 21987743.
Martínez-Romero C, García-Sastre A (November 2015). “Against the clock towards new Ebola virus therapies”. Virus Research 209: 4–10. doi:10.1016/j.virusres.2015.05.025. PMID 26057711.
Choi WY, Hong KJ, Hong JE, Lee WJ (January 2015). “Progress of vaccine and drug development for Ebola preparedness”. Clinical and Experimental Vaccine Research 4 (1): 11–6. doi:10.7774/cevr.2015.4.1.11. PMC 4313103. PMID 25648233.
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT, Thomas SJ (January 2017). “A Recombinant Vesicular Stomatitis Virus Ebola Vaccine”. The New England Journal of Medicine 376 (4): 330–341. doi:10.1056/NEJMoa1414216. PMC 5408576. PMID 25830322.
Ura T, Okuda K, Shimada M (July 2014). “Developments in Viral Vector-Based Vaccines”. Vaccines 2 (3): 624–41. doi:10.3390/vaccines2030624. PMID 26344749.

europa.eu

ema.europa.eu

“Ervebo EPAR”. European Medicines Agency (EMA) (2019年12月12日). 2020年7月1日閲覧。 Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
“Zabdeno EPAR”. European Medicines Agency (EMA) (2020年5月26日). 2020年7月23日閲覧。
“Mvabea EPAR”. European Medicines Agency (EMA) (2020年5月26日). 2020年7月23日閲覧。

fda.gov

FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 (PDF) (Report). U.S. Food and Drug Administration (FDA).
“Ervebo (Ebola Zaire Vaccine, Live) Suspension for intramuscular injection” (PDF). Merck Sharp & Dohme. 2021年4月8日閲覧。
“First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response”. U.S. Food and Drug Administration (FDA) (2019年12月19日). 2019年12月20日時点のオリジナルよりアーカイブ。2019年12月19日閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
“Ervebo”. U.S. Food and Drug Administration (FDA) (2019年12月19日). 2020年7月1日閲覧。

jnj.com

"Johnson & Johnson Announces European Commission Approval for Janssen's Preventive Ebola Vaccine" (Press release). Johnson & Johnson. 1 July 2020. 2020年7月16日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Stephen, Sam Laurel; Montini, Eugenio; Sivanandam, Vijayshankar Ganesh; Al-Dhalimy, Muhseen; Kestler, Hans A.; Finegold, Milton; Grompe, Markus; Kochanek, Stefan (2010-10). “Chromosomal Integration of Adenoviral Vector DNA In Vivo”. Journal of Virology 84 (19): 9987–9994. doi:10.1128/JVI.00751-10. ISSN 0022-538X. PMC 2937808. PMID 20686029.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W (August 2020). “Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial”. Lancet 396 (10249): 479–488. doi:10.1016/S0140-6736(20)31605-6. PMC 7836858. PMID 32702299.
Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H (November 2011). “Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy”. The Journal of Infectious Diseases 204 Suppl 3 (suppl 3): S1066-74. doi:10.1093/infdis/jir348. PMC 3203393. PMID 21987743.
Martínez-Romero C, García-Sastre A (November 2015). “Against the clock towards new Ebola virus therapies”. Virus Research 209: 4–10. doi:10.1016/j.virusres.2015.05.025. PMID 26057711.
Choi WY, Hong KJ, Hong JE, Lee WJ (January 2015). “Progress of vaccine and drug development for Ebola preparedness”. Clinical and Experimental Vaccine Research 4 (1): 11–6. doi:10.7774/cevr.2015.4.1.11. PMC 4313103. PMID 25648233.
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT, Thomas SJ (January 2017). “A Recombinant Vesicular Stomatitis Virus Ebola Vaccine”. The New England Journal of Medicine 376 (4): 330–341. doi:10.1056/NEJMoa1414216. PMC 5408576. PMID 25830322.
Ura T, Okuda K, Shimada M (July 2014). “Developments in Viral Vector-Based Vaccines”. Vaccines 2 (3): 624–41. doi:10.3390/vaccines2030624. PMID 26344749.

ncbi.nlm.nih.gov

Stephen, Sam Laurel; Montini, Eugenio; Sivanandam, Vijayshankar Ganesh; Al-Dhalimy, Muhseen; Kestler, Hans A.; Finegold, Milton; Grompe, Markus; Kochanek, Stefan (2010-10). “Chromosomal Integration of Adenoviral Vector DNA In Vivo”. Journal of Virology 84 (19): 9987–9994. doi:10.1128/JVI.00751-10. ISSN 0022-538X. PMC 2937808. PMID 20686029.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W (August 2020). “Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial”. Lancet 396 (10249): 479–488. doi:10.1016/S0140-6736(20)31605-6. PMC 7836858. PMID 32702299.
Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H (November 2011). “Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy”. The Journal of Infectious Diseases 204 Suppl 3 (suppl 3): S1066-74. doi:10.1093/infdis/jir348. PMC 3203393. PMID 21987743.
Choi WY, Hong KJ, Hong JE, Lee WJ (January 2015). “Progress of vaccine and drug development for Ebola preparedness”. Clinical and Experimental Vaccine Research 4 (1): 11–6. doi:10.7774/cevr.2015.4.1.11. PMC 4313103. PMID 25648233.
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT, Thomas SJ (January 2017). “A Recombinant Vesicular Stomatitis Virus Ebola Vaccine”. The New England Journal of Medicine 376 (4): 330–341. doi:10.1056/NEJMoa1414216. PMC 5408576. PMID 25830322.

nytimes.com

Corum J, Carl Z (2021年1月8日). “How Gamaleya's Vaccine Works”. The New York Times 2021年1月27日閲覧。

web.archive.org

“A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19”. EU Clinical Trials Register. European Union (2020年4月21日). 2020年10月5日時点のオリジナルよりアーカイブ。2020年8月3日閲覧。
“First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response”. U.S. Food and Drug Administration (FDA) (2019年12月19日). 2019年12月20日時点のオリジナルよりアーカイブ。2019年12月19日閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。

wikipedia.org

en.wikipedia.org

“Understanding and Explaining Viral Vector COVID-19 Vaccines”. U.S. Centers for Disease Control and Prevention (2021年2月25日). 2021年4月2日閲覧。
臨床試験番号 NCT02313077 研究名 "A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants" - ClinicalTrials.gov
臨床試験番号 NCT04400838 研究名 "Investigating a Vaccine Against COVID-19" - ClinicalTrials.gov
臨床試験番号 NCT04436471 研究名 "An Open Study of the Safety, Tolerability and Immunogenicity of the Drug 'Gam-COVID-Vac' Vaccine Against COVID-19" - ClinicalTrials.gov
臨床試験番号 NCT04436276 研究名 "A Study of Ad26.COV2.S in Adults" - ClinicalTrials.gov
臨床試験番号 NCT04505722 研究名 "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants" - ClinicalTrials.gov
FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 (PDF) (Report). U.S. Food and Drug Administration (FDA).
臨床試験番号 NCT04566770 研究名 "Phase IIb Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)" - ClinicalTrials.gov
“Ervebo EPAR”. European Medicines Agency (EMA) (2019年12月12日). 2020年7月1日閲覧。 Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
“First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response”. U.S. Food and Drug Administration (FDA) (2019年12月19日). 2019年12月20日時点のオリジナルよりアーカイブ。2019年12月19日閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
“Ervebo”. U.S. Food and Drug Administration (FDA) (2019年12月19日). 2020年7月1日閲覧。
“Zabdeno EPAR”. European Medicines Agency (EMA) (2020年5月26日). 2020年7月23日閲覧。
“Mvabea EPAR”. European Medicines Agency (EMA) (2020年5月26日). 2020年7月23日閲覧。

worldcat.org

search.worldcat.org

Stephen, Sam Laurel; Montini, Eugenio; Sivanandam, Vijayshankar Ganesh; Al-Dhalimy, Muhseen; Kestler, Hans A.; Finegold, Milton; Grompe, Markus; Kochanek, Stefan (2010-10). “Chromosomal Integration of Adenoviral Vector DNA In Vivo”. Journal of Virology 84 (19): 9987–9994. doi:10.1128/JVI.00751-10. ISSN 0022-538X. PMC 2937808. PMID 20686029.